Cold-EEZE: COLD-EEZE® LOZENGES NOT AFFECTED BY FDA ADVISORY FOR ZICAM® INTRA-NASAL PRODUCTS
COLD-EEZE® LOZENGES NOT AFFECTED BY FDA ADVISORY FOR ZICAM® INTRA-NASAL PRODUCTS
COLD-EEZE® LOZENGES NOT AFFECTED BY FDA ADVISORY FOR ZICAM® INTRA-NASAL PRODUCTS
Doylestown, PA, June 16 – The U.S. Food and Drug Administration (FDA) today advised consumers to stop using three intra-nasal products (gels and swabs) marketed over-the-counter as cold remedies under the Zicam® brand because the use of these intra-nasal products are associated with the loss of sense of smell (a condition called anosmia).
While these products are manufactured with a zinc ingredient, The Quigley Corporation, maker of the popular line of Cold-EEZE® zinc gluconate lozenges, assures consumers that their oral zinc lozenge products are not involved in this new FDA advisory, and that the Cold-EEZE® brand continues to be supported as safe and effective in clinical research. Only intra-nasal products have shown any association with anosmia.
“The introduction of zinc ions orally has not been connected with the loss of smell,” says Darrell T. Hulisz, R.Ph., PharmD, clinical pharmacist/researcher and associate clinical professor at Ohio Northern University College of Pharmacy. “The safe and efficacious use of oral zinc gluconate lozenges is well established.”
“The FDA has made a determination that the Zicam intra-nasal products have a growing body of evidence suggesting that they may pose a safety risk to consumers who use them,” says Albert Piechotta, executive director of communications at The Quigley Corporation. “Cold-EEZE zinc lozenges have been shown to safely reduce the duration and severity of cold symptoms by nearly half in two clinical studies and have no history of causing adverse events related to anosmia in clinical studies or safety studies.”
Since their introduction 14 years ago, Cold-EEZE lozenges have had an outstanding record of safety. Customers can be assured that Cold-EEZE lozenges will continue to be available and is not affected by the FDA’s decision to request Zicam remove its nasal products from store shelves.”
For more information about Cold-EEZE®, visit www.coldfight360.com.
Doylestown, PA, June 16 – The U.S. Food and Drug Administration (FDA) today advised consumers to stop using three intra-nasal products (gels and swabs) marketed over-the-counter as cold remedies under the Zicam® brand because the use of these intra-nasal products are associated with the loss of sense of smell (a condition called anosmia).
While these products are manufactured with a zinc ingredient, The Quigley Corporation, maker of the popular line of Cold-EEZE® zinc gluconate lozenges, assures consumers that their oral zinc lozenge products are not involved in this new FDA advisory, and that the Cold-EEZE® brand continues to be supported as safe and effective in clinical research. Only intra-nasal products have shown any association with anosmia.
“The introduction of zinc ions orally has not been connected with the loss of smell,” says Darrell T. Hulisz, R.Ph., PharmD, clinical pharmacist/researcher and associate clinical professor at Ohio Northern University College of Pharmacy. “The safe and efficacious use of oral zinc gluconate lozenges is well established.”
“The FDA has made a determination that the Zicam intra-nasal products have a growing body of evidence suggesting that they may pose a safety risk to consumers who use them,” says Albert Piechotta, executive director of communications at The Quigley Corporation. “Cold-EEZE zinc lozenges have been shown to safely reduce the duration and severity of cold symptoms by nearly half in two clinical studies and have no history of causing adverse events related to anosmia in clinical studies or safety studies.”
Since their introduction 14 years ago, Cold-EEZE lozenges have had an outstanding record of safety. Customers can be assured that Cold-EEZE lozenges will continue to be available and is not affected by the FDA’s decision to request Zicam remove its nasal products from store shelves.”
For more information about Cold-EEZE®, visit www.coldfight360.com.